{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Lee MS"],"funding":["The Ohio State University College of Medicine Office of Research","NIDDK NIH HHS","National Institute of Diabetes and Digestive and Kidney Diseases"],"pubmed_abstract":["Objective
To define the risk of laboratory abnormalities associated with commonly prescribed medications in the context of urinary stone disease (USD).Materials and methods
We used the Veterans Health Administration Corporate Warehouse to identify adults ≥ 18 years with an index episode of USD. The development of laboratory abnormalities for those ever versus never on preventive pharmacological therapy was then compared using separate Cox proportional hazards regression models for each laboratory abnormality-drug class combination, adjusting for baseline patient characteristics and time-varying medication use over the study period. To provide a sense for absolute risk, we then used the models to estimate 2-year predicted probabilities of developing a laboratory abnormality "],"journal":["Urology"],"pagination":["S0090-4295(25)01358-5"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12928847"],"repository":["biostudies-literature"],"pubmed_title":["Laboratory Abnormalities Associated With the Use of Preventive Pharmacological Therapy for Urinary Stone Disease."],"pmcid":["PMC12928847"],"funding_grant_id":["R01 DK121709"],"pubmed_authors":["Maya RG","Hsi RS","Valicevic A","Lee MS","Oerline MK","Shahinian VB","Patel S","Hollingsworth JM"],"additional_accession":[]},"is_claimable":false,"name":"Laboratory Abnormalities Associated With the Use of Preventive Pharmacological Therapy for Urinary Stone Disease.","description":"Objective
To define the risk of laboratory abnormalities associated with commonly prescribed medications in the context of urinary stone disease (USD).Materials and methods
We used the Veterans Health Administration Corporate Warehouse to identify adults ≥ 18 years with an index episode of USD. The development of laboratory abnormalities for those ever versus never on preventive pharmacological therapy was then compared using separate Cox proportional hazards regression models for each laboratory abnormality-drug class combination, adjusting for baseline patient characteristics and time-varying medication use over the study period. To provide a sense for absolute risk, we then used the models to estimate 2-year predicted probabilities of developing a laboratory abnormality ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-07-16T18:35:26.62Z","creation":"2026-07-09T11:15:07.638Z"},"accession":"S-EPMC12928847","cross_references":{"pubmed":["41423090"],"doi":["10.1016/j.urology.2025.12.008"]}}